Pregabalin Versus Celecoxib on Sevoflurane and Analgesic Consumption in Spine Fixation Surgery

Model scores of the 29,894 trials active now.

Model score 6% for any early termination, 2% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 10% of the time (273 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2020-02-01. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (lowers risk) · Wording Phrases that raised it: diabeticpainpregabalinneuropathycontrol
  Phrases that lowered it: effectefficacyelectivehistoryanti inflammatory
• Sponsor's past termination rate: 0% (lowers risk) · Sponsor's track record
• Minimum age: 21 (lowers risk) · Who can join
• Accepts healthy volunteers: No (raises risk) · Who can join
• Blinding: triple (raises risk) · Design
• Has a data monitoring committee: Yes (raises risk) · Design
• Disease area, cancer: No (lowers risk) · Disease area
• Responsible party: principal investigator (lowers risk) · Design
• Drug's FAERS reports marked serious: 62.5% (lowers risk) · Drug's FDA history
• Drug's FAERS reports with a death: 6.7% (lowers risk) · Drug's FDA history
• Design: parallel (raises risk) · Design
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Drug's FAERS reports before start: 240360 (lowers risk) · Drug's FDA history
• Primary purpose: treatment (raises risk) · Design
• Number of arms: 2 (raises risk) · Design
• Maximum age: 60 (lowers risk) · Who can join
• Sponsor's past trials: 2 (lowers risk) · Sponsor's track record
• Disease area, neurology: No (lowers risk) · Disease area

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Co-analgesic Effects of Dexamethasone and Pregabalin After Lumbar Slipped Disc Surgery NCT01811251 · started 2012 · scored riskier than 65% of active trials completed
• Pregabalin Compared to Gabapentin for Pain Control in Lumbar Disc Surgery NCT02120703 · started 2011 · scored riskier than 9% of active trials completed
• Safety and Efficacy of Pre-incisional Intravenous Ibuprofen to Reduce Postoperative Pain and Opioid Dependence After Posterior Cervical or Lumbar Instrumented Spine Surgery NCT02276911 · started 2015 · scored riskier than 83% of active trials terminated
• Preemptive Oral Gabapentin 600 mg in Reducing Morphine Requirement After Non Obstetric Lower Abdominal Surgery NCT04434430 · started 2019 · scored riskier than 7% of active trials completed
• A Multicenter Trial of the Efficacy and Safety of a New Formulation of Ibuprofen 800 mg Every 6 Hours in the Management of Postoperative Pain NCT02254525 · started 2012 · scored riskier than 18% of active trials terminated

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.